LATENT PREDICTORS OF HELLP SYNDROME: A COMPREHENSIVE ANALYSIS OF CLINICAL, GENETIC, AND MORPHOLOGICAL DETERMINANTS
DOI:
https://doi.org/10.5281/zenodo.17032777Abstract
HELLP (Hemolysis, Elevated Liver enzymes, Low Platelets) syndrome is one of the most aggressive and fulminant forms of secondary thrombotic microangiopathies (TMAs), often considered an extreme variant of severe preeclampsia or a distinct complication. Its clinical manifestations—massive hemolysis, a marked elevation of liver enzymes, and a critical drop in platelet count—are indicative of profound systemic damage associated with a high risk of multi-organ failure, disseminated intravascular coagulation (DIC), and maternal mortality, which can reach up to 3-5% according to various authors [1].
References
Sibai B.M., Ramadan M.K., Usta I., et al. Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome). Am. J. Obstet. Gynecol. 1993; 169(4): 1000-1006.
Erkılınç S., Eyi E.G.Y. Factors contributing to adverse maternal outcomes in patients with HELLP syndrome. J. Matern. Fetal Neonatal Med. 2017; Aug 8: 1-7.
Fakhouri F., Jablonski M., Lepercq J., et al. Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome. Blood. 2008; 112(12): 4542-4545.
Weiner Е., Schreiber L., Grinstein E., et al. The placental component and obstetric outcome in severe preeclampsia with and without HELLP syndrome. Placenta. 2016; 47: 99-104.
Tranquilli А.L., Landi B., Corradetti A., et al. Inflammatory cytokines patterns in the placenta of pregnancies complicated by HELLP (hemolysis, elevated liver enzyme, and low platelet) syndrome. Cytokine. 2007; 40(2): 82-88.
